Production , purification and preparation of various candidiate vaccines

各种候选疫苗的生产、纯化和制备

• 批准号: 8554137
• 负责人: Joseph Shiloach
• 金额: $ 31.56万
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8554137
• 关键词: Bacillus anthracis; Biotechnology; Bioterrorism; Clostridium; Collaborations; Conjugate Vaccines; Development; Diphtheria Toxoid; E coli polysaccharide K1; Evaluation; Haemophilus influenzae; Laboratories; MDCK cell; Malaria; Malaria Vaccines; Methods; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; Pertussis; Polysaccharides; Preparation; Production; Proteins; Public Health; Recombinants; Scientist; Shigella; Shigella flexneri; Structure; Toxin; Vaccines; Work; improved; influenza virus vaccine; influenzavirus; novel vaccines; transmission process; vaccine development

The Biotechnology Lab continued its collaborating work with the LDMI of the NICHD on the development of new vaccines against Shigella flexneri, Shigella Sonnie, Bortedella pertussis Haemophilus influenzae type A, Bacillus anthracis, influenza virus and malaria. Several proteins are being prepared for their evaluation as a potential candidates for conjugated polysaccharides vaccines, among them recombinant toxin A and toxin B of Clostridium difficle and recombinant diphtheria toxoid, recombinant pfs25H and pvs25H are being made for experimental malaria transmission blocking vaccine. The Biotechnology Lab continued its collaboration with the Malaria Vaccine Development Unit of NIAID working on improving the production of various experimental malaria vaccines. Working together with scientists from the FDA the laboratory is evaluating the potential production of influenza virus vaccine form the newly developed MDCK cells, and on the structure of the polysaccharide from E. coli K1 and Meningococcal C.

生物技术实验室继续与NICHD的实验室合作，开发针对福氏志贺菌、Sonnie志贺菌、百日咳杆菌、A型流感嗜血杆菌、炭疽杆菌、流感病毒和疟疾的新疫苗。目前正在制备几种蛋白质，以评价它们作为缀合多糖疫苗的潜在候选物，其中艰难梭菌的重组毒素A和毒素B以及重组白喉类毒素、重组pfs 25 H和pvs 25 H正在制备用于实验性疟疾传播阻断疫苗。 生物技术实验室继续与NIAID疟疾疫苗开发股合作，努力改进各种实验性疟疾疫苗的生产。 该实验室与FDA的科学家合作，正在评估新开发的MDCK细胞生产流感病毒疫苗的可能性，以及E. coliK1和脑膜炎球菌C.